论文部分内容阅读
解放军南京八一医院秦叔逵教授曾在第46届美国临床肿瘤学会(ASCO)年会上,报告他与中国医学科学院肿瘤医院孙燕院士共同牵头的“含奥沙利铂FOLFOX4方案与阿霉素随机对照治疗晚期不可手术肝细胞癌患者的大型国际多中心川期临床试验(EACH研究)”。在2014年第50届ASCO年会上,由秦叔逵教授与复旦大学附属肿瘤医院李进教授共同牵头的阿帕替尼治疗晚期胃癌的Ⅲ期临床研究入选消化道肿瘤(非结直肠癌)口头报告专场,并且收入了“Best of ASCO”优秀论文,成为中国学者在本届ASCO年会上唯一获此殊荣的重要研究。当问及秦叔逵教授,中国学者已经参与国际多中心临床研究十多年,对于中国临床研究的变化有何感受时,他非常精辟地说了这样一句话:“我们是从台下的听众,变成了台上的主宾。”
Qin Shuyi, a professor at the August Bay Hospital of PLA in Nanjing, reported at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO) that he co-led with Dr. Sun Yan, Cancer Hospital of Chinese Academy of Medical Sciences. “The combination of FOLFOX4 with oxaliplatin and doxorubicin Randomized controlled large international multicenter clinical trial (EACH) in patients with advanced non-operable hepatocellular carcinoma ”. At the 50th ASCO Annual Meeting in 2014, a Phase III clinical trial of apatitanib in the treatment of advanced gastric cancer co-led by Professor Qin Shuqiu and Professor Jin Li at the Affiliated Oncology Hospital of Fudan University was selected for oral report on gastrointestinal cancer (non-colorectal cancer) Special, and income “Best of ASCO ” outstanding papers, Chinese scholars in this ASCO annual meeting was the only important study of this award. When asked about Professor Qin Shuqiu and Chinese scholars who have participated in international multi-center clinical research for more than 10 years, he felt very incisive about the change of clinical research in China: “We are from the audience, Become a guest on the stage. ”